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In utero gene therapy (IUGT) to the fetal hematopoietic compartment could be used to treat congenital 
blood disorders such as β-thalassemia. A humanised mouse model of β-thalassemia was used, in which 
heterozygous animals are anaemic with splenomegaly and extramedullary hematopoiesis. Intrahepatic 
in utero injections of a β globin-expressing lentiviral vector (GLOBE), were performed in fetuses at E13.5 
of gestation. We analysed animals at 12 and 32 weeks of age, for vector copy number in bone marrow, 
peripheral blood liver and spleen and we performed integration site analysis. Compared to noninjected 
heterozygous animals IUGT normalised blood haemoglobin levels and spleen weight. Integration site 
analysis showed polyclonality. The left ventricular ejection fraction measured using magnetic resonance 
imaging (MRI) in treated heterozygous animals was similar to that of normal non-β-thalassemic 
mice but significantly higher than untreated heterozygous thalassemia mice suggesting that IUGT 
ameliorated poor cardiac function. GLOBE LV-mediated IUGT normalised the haematological and 
anatomical phenotype in a heterozygous humanised model of β-thalassemia.
β-thalassemia is caused by mutations in the β-globin (HBB) locus giving β-globin chain reduction. It is a 
common severe disease with 56,000 β-thalassaemia major (TM) births per year worldwide and an estimated 
5–7% carrier frequency in the general population, with increased frequency in risk ethnic groups such as 
Mediterranean, Middle Eastern, and South Asian1. TM requires regular blood transfusions and if left untreated 
is a life-threatening condition for which the only curative therapy - allogeneic haematopoietic stem cell (HSC) 
transplantation - is limited to a small percentage of patients with available HSC donors. It can be diagnosed in 
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utero, and many countries have efficient screening and prenatal diagnosis programs2 that may lead to a termina-
tion of pregnancy (TOP) if an affected fetus is found. Prenatal diagnosis can detect an affected fetus as early as ten 
weeks of gestation3.
In TM, ineffective erythropoiesis results in expanded marrow cavities that impinge on healthy bone result-
ing in osteoporosis and osteonecrosis. These can distort the cranium, and of facial and long bones. Symptoms 
include erythropoiesis in extramedullary hematopoietic sites, hepatosplenomegaly, and, in some cases, extramed-
ullary mass. Without transfusion support, 85% of patients with severe homozygous or compound heterozygous 
β-thalassemia will die by five years of age from severe anemia4. This is a problem in the countries where the cost 
or blood transfusion is prohibitively expensive and often unavailable.
Fetal therapy of an affected fetus would avoid termination of pregnancy, early death or life-threatening com-
plications for patients with no compatible donor. This would have an impact where α-and β-thalassemia are most 
prevalent, even where termination of pregnancy may not be available, and blood transfusions are prohibitively 
expensive5.
Possible curative options that show promise are (i) the autologous correction of β-thalassaemia patient HSCs 
through gene augmentation studies mediated by β-globin expressing lentiviral vectors and (ii) reactivation of the 
endogenous HBG through lentiviral-mediated gene silencing of HBG silencer genes (e.g. BCL11A)6.
Various groups have been trying to construct an ideal gene delivery vehicle, which will be able to correct 
the disease either in utero or postnatally7–11. We choose the GLOBE12,13 lentiviral vector for an in utero therapy 
approach in a novel humanised model of β-thalassemia14–17. The GLOBE LV, which is now in phase I/II clinical 
trial (NCT02453477) was previously shown to correct β-thalassaemia in murine (Miccio et al.)13 and human 
(Roselli et al.)12 haematopoietic progenitor cells. In the study of Miccio et al., the authors showed an in vivo selec-
tion of genetically modified erythroblasts in β-thalassaemia mice13 with 15–30% of maturing erythroblasts being 
sufficient for correction and correction of human HP cells respectively. Recently A.A. Thompson and colleagues 
showed correction of transfusion-depended β-thalassaemia and reduction or elimination of transfusion require-
ments using ex vivo gene therapy with LentiGlobin BB305 vector18.
In this study we used the humanised mouse model of β-thalassemia which had been generated by replac-
ing the mouse adult α- and β-globin genes with adult human α-globin genes and a human fetal to adult 
haemoglobin-switching cassette16,17,19. Two mouse models were used, one with functional HBB (B383: 
hBThal-Control) and one with non-functional HBB (B382: hBThal). The B382 with a human fetal to adult 
haemoglobin-switching cassette (non-functional HBB) kept in a homozygous human alpha globin and heterozy-
gous human fetal to adult Hb-switching cassette. The homozygous animals from the later mouse strain die within 
two weeks if left untreated. This provides a similar temporal onset of the disease as in humans (early years) if left 
untreated. Animals become severely anaemic after birth and die within approximately 2–3 weeks of age, similar 
to the affected human neonate. However, animals can be rescued from lethal anaemia by weekly blood transfu-
sions20–22. Heterozygous animals show features of thalassemia intermedia such as splenomegaly, extramedullary 
hematopoiesis, anaemia, and anisocytosis.
In this study, we show the phenotypic (haematological and anatomical) correction of the heterozygous ani-
mals using in utero gene therapy (IUGT) approach through prenatal intrahepatic injection of the GLOBE LV.
Results
In utero gene therapy corrects haemoglobin in a heterozygous humanised mouse model of 
thalassemia at 12 weeks’ post-IUGT. Results of surgery and postnatal outcome. In order to identify 
the true fetal and dam survival after in utero gene therapy delivery we analysed the fetuses at E18 after IUGT in 
two dams. In a representative dam, where all ten fetuses were injected, at post-mortem, a total of 3 fetuses were 
identified as alive, while the rest of the injected fetuses suffered with fetal demise. In another dam where all six 
fetuses were injected, three were identified as alive at E18. This gives a survival rate after injections of 37%. This 
was similar to the survival rate of 36% from IUGT to post-mortem analysis at either 12 or 32 weeks postnatally, 
suggesting that the loss was due to the in utero injection itself.
Examination of demised fetuses revealed that they probably died immediately after the injection since the 
fetuses were barely seen at the E18 time-point having been resorbed over the previous 4.5 days. Indeed, in some 
cases, only the placenta was visible when the dam was sacrificed. The fetuses which were collected at E18 were 
also genotyped to identify the presence of the homozygote, heterozygote and wild-type animals. The proportion 
of homozygous pups in uninjected litters at E18 was 25% from n = 3 dams.
Dam survival after IUGT was 100% (n = 9). All fetuses were injected in all litters n = 67 total injected; sur-
vival from IUGT to cross-fostering was n = 25. Overall pup survival to post-mortem analysis was 37% for all 
experiments. There was no difference in the weight of all groups at 12 Weeks (Untreated thalassaemia Control 
28.79 ± 2.08 vs Humanised Control 28.09 ± 2.12 vs IUGT 28.74 ± 1.41, p = 0.82, One Way ANOVA).
The animals were cross-fostered to CD1 time mated dams which delivered one day earlier. This was done to 
avoid maternal cannibalism and also to prevent the passage of maternal antibody against the transgenic protein 
in the milk. Genotyping at three weeks after birth identified thalassaemia animals all of which were heterozygous. 
There were no homozygous pups identified by genotyping suggesting that they had demised either in utero, after 
the intrahepatic injection, or just before cross-fostering as all live cross-fostered pups survived to genotyping. 
Wild-type animals were excluded from further analysis once identified.
Phenotype results. At 12 weeks of age, the peripheral blood haemoglobin concentration of treated heterozy-
gous pups was not significantly different to that of Humanised non-thalassemia control animals (11 ± 0.21 vs 
11 ± 0.22, p > 0.99, One Way ANOVA, Fig. 1B), and was significantly higher than the haemoglobin concentration 
of untreated heterozygous control pups (8.4 ± 0.17, p = 0.0001). The relative expression of the human beta-globin 
gene in the peripheral blood confirmed that the normalised haemoglobin concentration was due to the increased 
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expression of the transgene (n = 10, p = 0.039, One Way ANOVA, Kruskal-Wallis test, a Two-stage linear step-up 
procedure of Benjamini, Krieger and Yekutieli, Fig. 1D). At 12 weeks of age, the relative gene expression of human 
gamma-globin was lower in GLOBE, IUGT, treated compared to untreated heterozygous thalassemia pups 
(0.11 ± 0.024 versus 1.0 ± 0, n = 10, p = 0.0002, one-way ANOVA, Kruskal-Wallis test, a Two-stage linear step-up 
procedure of Benjamini, Krieger and Yekutieli, Fig. 1E). This confirmed that in treated heterozygous thalassemia 
pups, the human gamma to beta-globin switching cassette successfully switched human gamma-globin to beta 
and subsequently fetal to adult haemoglobin. i.e. there was no hereditary persistence of fetal haemoglobin which 
could have been responsible for the higher Hb. This production of transgenic beta-haemoglobin was also verified 
at a protein level using high-performance liquid chromatography (HPLC) where the presence of a human beta 
chain peak was seen in the treated heterozygous thalassemia pups 12 weeks after injection (Fig. 1F). Data from 
HPLC were quantified and show an increase in the expression of human beta-globin chain at a protein level 
(Fig. 1B). The alpha globin in the treated animals was also higher than untreated and the level of gamma-globin 
was not affected by IUGT.
Heterozygous humanised thalassemia animals show evidence of splenomegaly, extramedullary and abnormal 
full blood count indices. In IUGT 12 Weeks animals the spleen weight was significantly less (0.12 ± 0.0065) than 
Figure 1. Study Design and Phenotypic Correction at 12 Weeks. (A) Study design: Heterozygous males were 
mated with heterozygous females. At E13.5 in utero gene therapy was performed by injecting 20 μl of the 
GLOBE vector into the intrahepatic space of each fetus in the litter after exposure of the uterus at laparotomy. 
The dams were allowed to litter, and the pups were cross-fostered into CD1 time time-mated dams to avoid 
maternal antibodies towards the virus. Post-mortem and analysis were performed at 12 weeks in the first 
study and 32 weeks in the second. Any wild-type animals were excluded from analysis. (B) Measurement of 
Hemoglobin in Humanised Non-Thalassemia Control 11 ±  0.21 Versus Uninjected Thalassemia Control 
8.4 ± 0.17 Versus IUGT 12 Weeks 11 ± 0.22, n = 8, ***p < 0.0001, One Way ANOVA, Bonferroni’s Multiple 
comparisons test. (C) Quantification of High-Performance Liquid Chromatography showing an increase of 
both alpha and beta globins (p = 0.0044) with the gamma globin remaining stable and similar between the 
two groups. (D) Real Time PCR of human beta globin relative gene expression showing upregulation of the 
beta-globin gene in the IUGT treated animals compared to untreated thalassemia controls. Wild-type C57BL6 
and human blood were used as positive and negative primer controls, n = 10, p = 0.039, ANOVA, Kruskal-
Wallis test, Two-stage linear step up procedure of Benjamini, Krieger and Yekutieli. (E) Real Time PCR of 
human gamma-globin relative gene expression showing downregulation of the gamma-globin gene in the 
IUGT treated animals compared to untreated fetal thalassemia controls at E13.5, 0.11 ± 0.024 versus 1.0 ± 0, 
n = 10, p = 0.0002, ANOVA, Kruskal-Wallis test, Two-stage linear step up procedure of Benjamini, Krieger and 
Yekutieli. Wild-type C57BL6 and human blood were used as negative primer controls. (F) Representative figure 
of High-Performance Liquid Chromatography showing the presence of a human beta globin chain pick in the 
IUGT group.
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non-treated animals (0.31 ± 0.017, n = 8, p < 0.0001, One Way ANOVA), and similar to Non-thalassemia control 
animal20 (Fig. 2A). The haematological indices of IUGT mice, Red Blood Cell Count (Fig. 2B) and Hematocrit 
(Fig. 2C) were also corrected at 12 weeks to the levels of the Humanised Non-Thalassemia Control animals. The 
level of extramedullary hematopoiesis (ineffective erythropoiesis), indicated by the ratio of erythroid progen-
itor cells (CD71+Ter119+) outside the bone marrow was also significantly lower in IUGT 12 Weeks animals 
(p = 0.00075, One Way ANOVA) compared to untreated thalassemia controls and not statistically different from 
Figure 2. Correction of Hematological Indices and Extramedullary Hematopoiesis. (A) Spleen weight in 
IUGT 12 Weeks animals was significantly lower 0.12 ± 0.0065 than untreated thalassemia controls 0.31 ± 0.017, 
n = 8, p < 0.0001 and similar to Humanised Non-Thalassemia Control 0.098 ± 0.0031, One Way ANOVA, 
Bonferroni’s Multiple comparisons test. (B) Red Blood Cell Count in IUGT 12 Week animals was significantly 
higher 9.36 ± 0.27 10^12/L, n = 8 than untreated thalassemia controls 6.23 ± 0.45 10^12/L, n = 8, p = 0.0015 
and similar to Humanised non-thalassemia controls 8.47 ± 0.57 10^12/L, n = 8, p = 0.089, One Way ANOVA, 
Bonferroni’s Multiple comparisons test. (C) The Hematocrit in IUGT 12 Week animals was significantly 
higher 41.79 ± 1.76%, n = 8, than untreated thalassemia controls 27.19 ± 2.02, n = 8, p = 0.0025 and similar to 
Humanised non-thalassemia controls 41.76 ± 2.80, n = 8, p > 0.99, One Way ANOVA, Bonferroni’s Multiple 
comparisons test. (D) Extramedullary Hematopoiesis in the Spleen was significantly lower in IUGT 12 Week 
animals 6.57 ± 1.78, n = 4, versus uninjected thalassemia controls 23.10 ± 4.57, n = 3, p = 0.00075 and similar 
to Humanised non-thalassemia controls 3.69 ± 0.41, n = 6, p = 0.64. Similarly, in the Liver, the level of EMH 
was lower in the IUGT 12 Week animals 0.74 ± 0.042, versus uninjected thalassemia controls 5.99 ± 0.87, 
n = 5, p = 0.10 and comparable to Humanised non-thalassemia controls 0.75 ± 0.091, n = 4, p > 0.99, One Way 
ANOVA, Bonferroni’s Multiple comparisons test. (E) Hematoxylin & Eosin light microscope images showing 
areas of extramedullary hematopoiesis (arrows) in the Spleen (Scale Bar 100 μm) and Liver (Scale Bar 50 μm).
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Humanised Non-Thalassemia Controls (p = 0.1, One Way ANOVA)21 (Fig. 2D). The reduction of extramedullary 
hematopoiesis was also confirmed by H&E staining of spleen and liver slides (Fig. 2E). These results are compa-
rable to previous studies done on adult thalassemia mice10,12,22.
Use of MRI techniques to monitor disease progression in animals treated with IUGT. In our 
second study, the in-utero gene transfer was performed as before, but the animals were sacrificed at 32 weeks of 
age having had MRI assessment two weeks before post-mortem. The animals were also genotyped, and wild-type 
animals were excluded from the analysis. The hemoglobin levels in the IUGT 32 Weeks group were also signif-
icantly higher (9.91 ± 0.36, n = 8) than that of the uninjected thalassemia control animals (8.42 ± 0.167, n = 8, 
p = 0.0053) but not significantly different from the humanised non-thalassemia control (10.87 ± 0.21, n = 8, 
p = 0.1, One Way ANOVA, Bonferroni’s Multiple comparisons test, Fig. 3A). The weight of the spleen was also 
significantly lower (0.2 ± 0.03, n = 8) than that of the uninjected group (0.309 ± 0.017, n = 8 p = 0.006), though 
significantly different from humanised non-thalassemia control group (0.1 ± 0.0031, n = 8, p = 0.01, Fig. 3B).
There was a difference in animal weight in the IUGT 32 Weeks group which was higher (38.03 ± 2.93, 
n = 6, p = 0.01, One Way ANOVA, Bonferroni’s Multiple comparisons test) than the uninjected Thalassaemia 
(28.97 ± 1.4, n = 9) and the age-matched humanised Non-Thalassaemia control (28.46 ± 1.53, n = 8) (Fig. 3C). 
This might be due to the viral integration to Socs6, which was observed during the site integration studies.
Figure 3. Long Term Correction and functional Assessment using MRI Techniques. (A) Hemoglobin levels 
in the IUGT 32 Weeks animals were significantly higher 9.91 ± 0.36, n = 8, than uninjected thalassemia 
controls 8.42 ± 0.167, n = 8 p = 0.0053 and similar to Humanised non-thalassemia control 10.87 ± 0.21, n = 8, 
p = 0.1, One Way ANOVA, Bonferroni’s Multiple comparisons test. (B) Spleen weight in the IUGT 32 Weeks 
animals was significantly lower 0.2 ± 0.03, n = 8 than uninjected thalassemia controls 0.309 ± 0.017, n = 8 
p = 0.006 and similar but also significantly different to Humanised non-thalassemia control 0.1 ± 0.0031, 
n = 8, p = 0.01, One Way ANOVA, Bonferroni’s Multiple comparisons test. (C) Animal weight was similar in 
uninjected Thalassemia 28.97 ± 1.4, n = 9 and Humanised Non Thalassemia 28.46 ± 1.53, n = 8, p = 097, control 
animals, but significantly higher in IUGT 32 Weeks animals 38.03 ± 2.93, n = 6, p = 0.01, One Way ANOVA, 
Bonferroni’s Multiple comparisons test. (D) Spleen Volume to Animal Mass Ration (mm3/g) as measured by 
MRI was significantly lower in IUGT 32 Weeks animals 5.19 ± 1.20, n = 6 than Uninjected Thalassemia controls 
10.97 ± 1.78, n = 6, p = 0.0012 and similar to Humanised non-thalassemia control 3.54 ± 0.28, p = 0.24, One 
Way ANOVA, Bonferroni’s Multiple comparisons test. (E) Stroke Volume (in ml) as measured by MRI was not 
significantly different in any of the groups at 32 weeks. IUGT 32 Weeks 0.029 ± 0.0022, n = 6 versus Uninjected 
Thalassemia control 0.03 ± 0.0047, n = 6, p = 0.987 versus Humanised Non-thalassemia control 0.032 ± 0.0021, 
n = 4, p = 0.902, One Way ANOVA, Bonferroni’s Multiple comparisons test. (F) Left Ventricular Ejection 
Fraction as measured by MRI (%) was significantly higher in the IUGT 32 Weeks group 59 ± 12, n = 6 than 
uninjected thalassemia control 50 ± 2.8, n = 6, p = 0125 and not significantly different from the Humanised 
non-thalassemia control 68 ± 0.41, n = 6, p = 0.91, One Way ANOVA, Bonferroni’s Multiple comparisons test.
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A preclinical MRI assessment was used to investigate, in vivo, the disease progress after in utero gene therapy 
as described23. Spleen volume was initially measured using MRI, and this was then calculated as an organ volume 
to mass ratio for a more accurate representation of organ volume.
The Spleen Volume to Animal Mass Ration (mm3/g) was lower in IUGT 32 Weeks animals 5.19 ± 1.20, 
n = 7 than of the Uninjected Thalassaemia controls 10.97 ± 1.78, n = 7, **p = 0.015 and similar to Humanised 
non-thalassaemia control 3.54 ± 0.29, p = 0.24. This confirmed that the spleen volume was reduced, which was 
measured, without the need to sacrifice any of the animals (Fig. 3D). The heart stroke volume remained the same 
after IUGT (0.029 ± 0.0022ml, n = 6 versus Uninjected Thalassemia control 0.03 ± 0.0047ml, n = 6, p = 0.987 
versus Humanised Non-thalassemia control 0.032 ± 0.0021ml, n = 4, p = 0.902, One Way ANOVA, Bonferroni’s 
Multiple comparisons test, Fig. 4E). This confirms that IUGT does not cause any structural defect, which was also 
confirmed on histopathological examination.
Encouraging results have arisen from the finding that the left ventricular ejection fraction (%) was increased 
in the IUGT 32 Weeks group (70.85 ± 1.58, n = 6) compared to the uninjected thalassaemia group (50.40 ± 2.83, 
n = 6, p = 0.0024) but was not different to the Humanised non-thalassaemia control group (68.00 ± 0.41, n = 6, 
p = 0.34, One Way ANOVA, Bonferroni’s Multiple comparisons test, Fig. 3F). We hypothesised that the iron 
accumulation in control non-injected group caused a reduction in the ejection fraction, which did not occur in 
the IUGT treated animals that had improved cardiac function24–26.
Monitoring Iron accumulation in thalassemia animals using MRI T2* techniques. The IUGT 32 
Weeks animals were scanned using MRI T2 and T2* relaxation times.
Tissue iron can be detected indirectly by measuring, using MRI, the relaxation times of hydrogen nuclei 
affected by ferritin and hemosiderin iron. The proton relaxations times are shortened as a result of the iron, spe-
cifically T2. The presence of blood can spoil the myocardium and blur its borders. This can be addressed by using 
T2* which excludes the signal from blood, using multiecho images in late diastole27.
T2 relaxation time was longer in IUGT 32 Weeks in the Heart 24 ± 5.5, n = 6 compared to Uninjected 
Thalassaemia Control 13 ± 0.83, n = 6, p = 0.26 and shorter, comparable to Humanised Non-Thalassaemia 
Control 28 ± 2.8, n = 6, p = 0.49. The T2 relaxation time of the untreated thalassaemia control was lower 
(p = 0.012) than the humanised non-thalassaemia control (Fig. 4B).
The T2 and T2* relaxation times in the spleen of the IUGT group were shortened compared to Humanised 
Non-Thalassaemia Control. No difference was seen between the IUGT group and the Thalassemia control, which 
was unexpected (Fig. 4D,G). This might be because of the increased breaking down of erythrocytes and sub-
sequently iron accumulation in the spleens of the thalassaemia animals (IUGT and Thalassemia Control). The 
excess iron accumulation in the thalassaemia animals could be due to dietary iron, and excess accumulation could 
be specific to the animal model.
Even though the T2* in IUGT 32 Weeks was similar to uninjected Thalassemia Control group, representative 
Pearl stains from an animal with successful correction of the defect (HB:12.5g/dl) showed less iron pigmentation 
compared to an untreated thalassemia control (Hb:9.0g/dl) (Fig. 4A).
T2 relaxation times in the liver of IUGT 32 Weeks were similar to Non-Thalassaemia Control and different 
from the uninjected Thalassaemia Control group (Fig. 4C). This was not the case for the T2* relaxation times 
in the liver which were different to the Non-Thalassaemia Control and similar to the uninjected Thalassaemia 
Control group (Fig. 4F).
Non Invasive disease progress monitoring is possible with MRI, which corresponds to dry weight measure-
ments23. For this experiment T2* was more accurate that T2 in the heart even through T2 had the same trend as 
T2*. This was also reported by L Jackson et al.23.
Site Integration (SI) Studies in IUGT 12 Weeks Recipients. Vector integration studies were done in 
the animals which were sacrificed at 12 weeks. The integration site analysis was done on bone marrow and liver. 
Vector Integration Studies in IUGT 12 Weeks animals showed no similar integration sites (Fig. 5). The mean 
vector copy number (VCN) in the IUGT 12 Weeks group, in the liver, was 0.093 ± 0.14, n = 10 and the cor-
responding integration sites were 60.56 ± 30.73 (Fig. 6G). The VCN in the bone marrow was 0.0059 ± 0.0014, 
n = 10 and the corresponding integration sites were 9.25 ± 4.27 (Fig. 6H). No similar integration sites were found 
during the vector integration site analysis. Cumulatively the number of integration sites in the liver was 504 
and in the bone marrow 51. The SI study highlighted the importance of investigating the specific vector in each 
biological application (IUGT) before human application. Even though oncogenesis through viral genome inte-
gration is intrinsically less likely in terminally differentiated cells, this is not the case for rapidly dividing cells 
of the haematopoietic lineage28. Themis and colleagues found a high incidence of hepatocellular carcinoma in 
mice receiving intravenous vitelline vein injection of the Equine Immune Anaemia Virus (EIAV) SMART 2hFIX, 
SMART 2Z, and SMART 3NZ lentiviral vectors in utero, but no oncogenesis was observed in HIV-1 based vector 
injections using the same route29. Thus the particular vector type may be of importance in the development of 
oncogenesis. Further studies suggest that the fetal mouse may be a sensitive genotoxicity model that exposes par-
ticular lentiviral-associated mutagenesis resulting in liver oncogenesis30. In this study, we observed integration to 
Peg12 gene which is associated with tumorigenesis but no hepatocellular carcinomas were observed at any time 
point. We did observe that IUGT animals were significantly heavier than non-thalassemic controls at 32 weeks. 
A possible explanation is integration to the gene SOCS-6, which was observed during the site integration studies. 
Socs-6 is involved in IGF-1 signalling and integration to the its site might have caused overexpression of the gene 
resulting to a significant weight difference31,32. Also, SI was observed in genes which are related to the develop-
ment and function of the nervous system and also spermatogenesis. A future repeat study should include an 
assessment of the neural development of the offspring and also their reproductive potential, especially in males.
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Figure 4. Iron Accumulation Assessment using MRI. (A) Representative Pearl Stained slides showing increased 
iron accumulation in the spleen and liver of the uninjected animals compared to IUGT 32 Weeks, (Scale Bar 
50 μm). (B) T2 relaxation times for the IUGT 32 Weeks group, were not different in the Heart (p = 0.26–0.98, 
one-way ANOVA, Bonferroni’s Multiple comparisons test) compared to uninjected thalassemia control. (C) T2 
relaxation times were different in Liver of the IUGT 32 Weeks group (13.5 ± 1.65 vs 8.068, n = 6, p = 0.0017) 
compared to uninjected thalassemia control and similar to Humanised non-thalassemia control (p = 0.52, one-
way ANOVA, Bonferroni’s Multiple comparisons test). (D) T2 relaxation times in IUGT 32 Weeks group were 
not significantly different in Spleen (p = 0.41, one-way ANOVA, Bonferroni’s Multiple comparisons test) when 
compared to uninjected thalassemia control. (E) T2* relaxation times were different in the Heart of the IUGT 
32 Weeks group (19 ± 1.40 vs 8.07 ± 0.77, n = 6, p = 0.0019) compared to uninjected thalassemia control and 
similar to Humanised non-thalassemia control (p = 0.32, one-way ANOVA, Bonferroni’s Multiple comparisons 
test). (F) T2* Relaxation Times in the Liver of IUGT 32 Weeks animals were significantly shortened 5.36 ± 0.91, 
n = 6 compared to Humanised Non-Thalassemia Control 9.34 ± 0.83, n = 6, p = 0.008 but not significantly 
different from the uninjected Thalassemia Control group, 4.76 ± 0.73, n = 6, p = 0.61, one-way ANOVA, 
Bonferroni’s Multiple comparisons test. (G) T2* in the spleen of IUGT 32 Weeks were significantly shortened 
0.81 ± 0.27, n = 6 compared to Humanised Non-Thalassemia Control 1.72 ± 0.09, n = 6, p = 0.02 but not 
significantly different from the uninjected Thalassemia Control group, 0.60 ± 0.21, n = 6, p = 0.48, one-way 
ANOVA, Bonferroni’s Multiple comparisons test.
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Vectors need to be assessed for safety and shown to have low oncogenic potential, in the actual biological 
system since the integration profile of the same vector may differ in different cell types, ex vivo and in vivo and 
during different developmental stages, before gene therapy application33. The safety in such system needs to be 
addressed34.
Discussion
In this study, we show successful phenotypic correction of thalassaemia intermedia in a humanised mouse model 
using an in-utero gene therapy approach. Normalisation of haemoglobin, spleen size and a reduction in the level 
of extramedullary haematopoiesis were the main findings of this preclinical study. We proved that there was a 
successful fetal to adult haemoglobin switch in the treated mice, as this was necessary to demonstrate that the 
improved phenotype was due to the IUGT. In vivo mouse, MRI was used to monitor the disease23 and showed 
improved cardiac function in the IUGT treated pups, even at 32 weeks after birth. We hypothesise that this was 
mediated through reduced iron accumulation in the heart.
Fetal application of gene therapy in mouse models of congenital disease such as haemophilia A35 and B36, 
congenital blindness37, Crigler-Najjar type 1 syndrome38 and Pompe disease (glycogen storage disease type 
II)35–39 have previously shown phenotypic correction of the condition. Fetal gene therapy has also been found to 
prevent the development of fetal structural anomalies. For example transient transduction of the periderm via 
intra-amniotic delivery of adenoviral vector encoding transforming growth factor β3 (TGFβ3) prevents cleft pal-
ate in a mouse model of disease40. For obstetric conditions that affect the fetus, maternal uterine artery injection 
of adenovirus containing the vascular endothelial growth factor (VEGF) gene improves fetal growth in growth 
restricted sheep and guinea pigs41,42. With regard to thalassaemia specifically a study by May et al.,43 showed that 
Figure 5. Site Integration Analysis. Vector integration studies were done in the animals which were sacrificed at 
12 weeks. The integration site analysis was done on bone marrow and liver. No similar sites were observed.
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gene transfer using a LV that contained proximal and distal regulatory elements with a large segment of the LCR 
(TNS9) could correct β-thalassaemia in mice, with an average increase in Hb by 3–4g/dL per vector copy and 
improvement of haematological indices. Similar studies have been published using other thalassaemia mouse 
models but with variable results8,43–46.
The target cell niche in this study was the expanding population of fetal liver haematopoietic stem cells. There 
are intrinsic differences between fetal and adult HSCs properties especially fetal liver HSCs which can give rise 
to thymocytes, especially Tregs which are responsible for promoting tolerance to self and potentially foreign 
antigen47. The fetal to adult switch in these HSC properties occurs between week one and two after birth in 
mice. During fetal life, the HSC pools in the fetal liver are actively cycling and rapidly expanding whereas, once 
the HSCs reach the fetal bone marrow, they become quiescent. This property of fetal HSC pools in the liver and 
their potential of thymic repopulation may be an added advantage for intrahepatic IUGT48 which is easily able 
Figure 6. Vector Copy Number, Genotyping and Blood Film Analysis. (A) Common Integration sites in 
IUGT 12 Weeks animals. (B) Sequencing of the GLOBE plasmid. (C) Representative map of GLOBE Vector. 
(D) Representative blood film of mouse peripheral blood showing normal profile (Scale Bar 20 μm). (E) 
Representative Blood film of mouse blood from non-treated control thalassemia group showing moderate 
anisocytosis, polychromatic cells and a mixed population of normocytes, schistocytes, crenated cells and 
acanthocytes (Scale Bar 10 μm). (F) Genotyping of the mice showed heterozygosity for the human γβ0 switching 
cassette. Agarose gel electrophoresis of the PCR products of the IUGT, positive controls, and wild-type mice 
DNA. The mouse β-globin product is 429 bp in size, and the human γβ0 knocked-in product is 323 bp in size. 
Heterozygous mice exhibited both products. Homozygous mice showed only one product at 323 bp (not shown 
here). All the treated mice were heterozygous except for WT1 and WT2 which showed only the mouse β-globin 
product similar to the wild type. None of the treated mice were homozygous for the human γβ0 product. (G) 
Liver VCN (0.093 ± 0.14, n = 10) of individual animals in IUGT 12 Weeks with corresponding Liver Integration 
sites (60.56 ± 30.73, n = 10) and hemoglobin levels 11.22 ± 0.21. (H) Bone Marrow VCN (9.25 ± 4.27, n = 10) of 
individual animals in IUGT 12 Weeks with corresponding Bone Marrow Integration sites (0.0059 ± 0.0014) and 
hemoglobin levels (11.22 ± 0.21).
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to direct gene transfer to the fetal liver through direct injection. Fetal liver HSCs are also capable of repopulating 
five times more effectively long term than short term49. Any manipulation of liver HSCs should have a long-term 
effect, ideally permanent, especially if these cells migrate to the thymus47. Intrahepatic fetal gene transfer to hae-
matopoietic progenitors has also been demonstrated in primates where the maximum effect was achieved using 
lentiviral vectors50.
Correction of haemoglobin was achieved with a low VCN of 0.093 in the liver. This is similar to the findings 
of Miccio et al.13 where correction of haemoglobin was achieved with an HSC VCN of <1 (0.2–0.9)13 in adult 
mice using ex vivo transduction of CD34+ HSCs before reinfusion in an autologous setting. The liver VCN 
in this study is 5–10 times lower than the HSC VCN that Miccio et al. observed13. The VCN in the liver was 
expressed in cells from the whole liver cell population and not only on the HSCs. There is a marked discrepancy 
between the VCN in the BM and that in the liver. This can be explained by the fact, that possibly, a large percent-
age of non-hematopoietic (off-target) cells were transduced following the direct intrahepatic lentiviral injection. 
Other authors have demonstrated that non-haematopoietic cells are transduced in an intrahepatic IUGT. The 
developmental stage of each organ, in this case the liver, could determine the susceptibility to in utero gene 
transfer and transgene expression51. The efficiency and distribution of transduction, is also highly depended on 
the type of vector used, as well as, the route of administration52. This could raise safety concerns, even though in 
a Cynomolgus Macaque model no tumours were observed, 6 years post IUGT, with an Adeno Associated viral 
vector. The authors, in this non-human primate study, addressed the importance for life long surveillance53. Thus, 
the VCN in the HSCs residing in the liver will be even lower. The use of direct in utero gene therapy, took advan-
tage of the high proliferation rate of the fetal HSCs which resulted in an adequate number of transduced daughter 
cells that were able to correct the phenotypic Hb defect. It was not possible to do individual sorting of HSCs from 
each transduced mouse due to the minimal amount of tissue collected and the scope of analysis initially planned 
such as EMH, histology and HPLC. Thus, we were unable to calculate the VCN in the HSC population only and 
instead present data on the VCN for the whole heterogeneous population of hepatocytes and whole bone marrow. 
It was unexpected that a level of gene correction (VCN) in the BM of 0.5% resulted in such a substantial boost 
in hemoglobin levels in the periphery. It is possible that the HSCs might have had a greater percentage of initial 
correction since the fetal liver is mainly made of HSC progenitors. Alternatively this result may not be true as we 
concentrated on analysis of the whole bone marrow rather than just the BM HSCs and our VCN result may have 
been lowered due to dilution. Further studies are needed to confirm this effect. Previous studies have found low 
genotoxicity of lentiviral vector integration in mice that are prone to developing tumours33. Nevertheless, it is an 
important safety consideration to keep the VCN as low as possible whilst maintaining the efficacy of the gene 
transfer.
The humanised mouse model of beta thalassaemia14,15,17,19 that we used is unique in that the fetal mice produce 
human gamma-globin (human fetal haemoglobin) in utero15, and have a human gamma to beta switching cassette 
which results in the death of homozygous animals within two weeks of birth, as the production of defective beta 
globin takes over. Homozygous animals can be rescued postnatally using regular blood transfusions16. This model 
allows human beta-globin producing vectors to be tested in utero12,13,54,55, and since the in utero phenotype is less 
severe than of other thalassaemia mouse models, eg th3, it allows the evaluation of IUGT to rescue the mouse 
model in utero and post-natally45,56.
In the first cohort (12 Weeks), where the animals were analysed at 12 weeks after birth, we observed normal-
isation of the phenotype with functional correction of anaemia, excessive extramedullary haematopoiesis and 
the other abnormal haematological indices. Blood films and H&E were also examined by an expert (University 
of Cambridge, Veterinary College). There was no evidence of malignancy and no abnormal looking red blood 
cells in the corrected (Hb > 10.0g/dl) animals (Fig. 6D). On the contrary in the untreated animals (Hb < 9.0g/dl), 
we observed the presence of moderate anisocytosis, polychromatic cells and a mixed population of normocytes, 
schistocytes, crenated cells and acanthocytes21 (Fig. 6E).The presence of normal blood films in the treated animals 
compared to untreated was a confirmatory result. To confirm the presence of normal Hb we used real-time PCR 
and high-performance liquid chromatography to demonstrate beta-globin gene expression with downregula-
tion of the gamma-globin gene as well as the additional peak from the beta globin chain in HPLC. These results 
excluded the hereditary persistence of fetal haemoglobin which could have contributed to the phenotypic correc-
tion of the overall haemoglobin.
In the long term 32-week postnatal group, the phenotypic correction appeared to be less effective as in the 
group analysed at 12 weeks after birth suggesting that the effect may reduce over time. This could be due to 
transcriptional silencing of the transgene57 or even due to epigenetic changes leading to deactivation of the 
beta-globin gene as the pups grew58,59. This was evident in the lower Hb concentration at the later time point 
(9.91 ± 0.36g/dl at 32 weeks’ vs 11 ±  0.22g/dl at 12 weeks), although the haemoglobin concentration at 32 weeks 
post-delivery was still significantly higher than that of age-matched controls. Histological analysis of the animals 
showed a correlation of spleen hyperplasia with iron deposits in the spleen, moderate anisocytosis and anaemia.
In the long-term group, MRI was used as a novel method of monitoring in utero gene therapy functional 
success (left ventricular ejection fraction, spleen volume, iron overload)60–63. We found that MRI can be used to 
monitor the disease progress, using T2 or T2* without sacrificing the animal. T2* is currently used clinically for 
the non-invasive diagnosis of iron overload in both heart and liver. It is also used for the assessment of the thal-
assemia major patient prior to stem cell transplantation64. This study confirms that this can be applied in small 
animal studies which can be used for the non-invasive assessment of new therapies23.
We did not observe any rescued homozygous pups in the genotyped litters; indeed, given the dam numbers 
and from previous studies in this specific humanised mouse model, we would have expected to have at least 
5–6 (25% of the total) homozygous pups if they were corrected. The only homozygote pup had to be culled 
at 14 days of age, due to severe illness, and haemoglobin measurement showed severe anaemia (3g/dL). All 
live cross-fostered pups survived to genotyping. There are a number of possible reasons for this low survival of 
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homozygote injected pups. It is possible that the treated homozygous pups demised in utero after the intrahepatic 
surgery or in the first hours after birth before they were cross-fostered due to a higher susceptibility to miscarriage 
or perinatal loss. Pups were usually born overnight and immediate cross-fostering was not possible as there was 
not always staff available to transfer them to the foster mother. It is also possible that homozygote rescue was 
incomplete rendering the born homozygote newborn pups more susceptible to being rejected or attacked and 
eaten by their mother. This has been reported in other studies where fetal intervention occurred65. Future studies 
using a higher titre of the vector will be conducted to determine whether this improves survival in the homozy-
gous pups.
In this study, we show that targeting the specific stem cell niche66,67 early enough in gestation with gene ther-
apy could be critical for fetal gene transfer, especially if most of the haematopoietic stem cells are within the 
compartment, in this case, the liver. Alternative routes such as intraperitoneal and intravascular injection need 
investigation to achieve a phenotypic cure, especially rescuing the homozygous animals. Boelig et al. found that 
the intravenous route was most successful for achieving rapid diffuse donor cell population of the fetal liver after 
in utero hematopoietic cell transplantation in mice68. Whether this achieves the same effect for fetal gene therapy 
remains to be seen. Importantly for clinical translation, the tissues were studied by an expert, and no animals 
were found to have malignancy, which is in keeping with other studies using this stable GLOBE vector13,18. This 
can also be confirmed that GLOBE vector is currently used in Phase II clinical trial, using autologous stem cell/
gene therapy approach in adult patients69. The number of vector integration sites corresponded to the vector copy 
number, even though this was low. This could be a sign that if higher VCN is achieved, the level of haemoglobin 
could also rise.
The integration site analysis revealed integration to be associated with the neural system, stem cells, spermat-
ogenesis and also with an oncogene. This must be carefully studied since the potential of tumor formation was 
shown to be high in a fetal context when using certain lentiviral vectors29. This also supports the use of an ex-vivo 
gene therapy approach using amniotic fluid stem cells or other highly efficient HSC progenitors70.
One of the benefits of perinatal treatment lies in the potential to limit organ damage through early inter-
vention. Also, applying a therapy to the fetus, where stem cell proliferation is high, results in a higher number 
of transduced cells, which leads to a better therapeutic effect71. The fetus also offers a size advantage, allowing 
a higher vector-to-target cell ratio. Certain organs that are challenging to target after birth may be more easily 
accessible in the fetus due to their developmental stages or relative immaturity72–75. The fetal epidermis is an 
example of this, as it undergoes remodelling by programmed cell death and is replaced by mature keratinocytes. 
The epidermis forms a thick barrier to gene transfer following birth76 but could be better targeted in utero77.
One of the main obstacles of postnatal gene therapy is the development of an immune response against the 
transgenic protein or the vector78. This is of particular importance when gene therapy aims to correct a genetic 
disease, which completely lacks a gene product. It is also possible that some patients may have pre-existing anti-
bodies to the viral vector that will inhibit long-term expression of the transgenic protein; this will limit therapeu-
tic efficacy and prevent repeated vector administration. For example, pre-existing neutralising antibodies against 
adeno-associated virus (AAV) serotype 2 have been shown to interfere with AAV2 vector-mediated factor IX 
(FIX) gene transfer to the liver78–81. Delivering foreign protein to the fetus can provide an advantage of immune 
tolerance during fetal life, a concept first suggested more than 60 years ago82,83. Induction of tolerance relies on 
the introduction and expression of the foreign protein early in gestation before the immune system is fully devel-
oped. The protein needs to remain at a detectable level within the fetus and presented to the thymus at the correct 
time84–88. In a postnatal treatment this can be achieved by ex-vivo correction of autologous HSCs, which will 
prevent an immune response, since the immune system will recognise the autologous, corrected cells as self. This 
can be demonstrated in a study, by A Thompson and colleagues. Using the BB305 vector, it reduced or eliminated 
the requirement for blood transfusions in 22 patients with severe β-thalassemia. No complications or reactions 
to the vector were reported18.
IUGT was delivered at embryonic day (E13.5) just before the time of HSC fetal bone marrow colonisation in 
mice, which occurs around E16-E1789, and which corresponds to an equivalent of 10 to 12 weeks of gestation in a 
human fetus90. Fetal gene transfer to the haematopoietic compartment91 may offer a third option to couples with 
a prenatal diagnosis of a fetal congenital blood disorder, especially in the beta haemoglobinopathies92. For human 
therapy, non-invasive prenatal diagnostic techniques are being developed using maternal blood to diagnose fetal 
thalassaemia from 8–10 weeks of gestation93. This would allow enough time to deliver gene therapy to the human 
fetus using ultrasound-guided intrahepatic injection. Using this methodology, no ex-vivo expansion and correc-
tion of the appropriate haematopoietic progenitors is required. More animal studies are required with the aim to 
rescue the homozygous mouse model. If this is successful, treatment could even be applied in low-income coun-
tries where the palliative cost of homozygous patients is unsustainable for the local health systems94–96. In order to 
reach the clinic, a gradual progression from small animal disease models, such as the mouse, followed by studies 
in larger animals, for example sheep to test the feasibility and safety of the delivery method will be necessary. A 
reproductive toxicology study would then be required, which might be performed either in rabbits or possibly in 
non-human primates before establishing a fist-in-human clinical trial of fetal gene therapy73,97.
Methods
Animals, animal care, and procedures. Humanised CA mice (α2α1/α2α1, γ(HPFH117) β0/+, 
Heterozygous Thalassemia) and the HbA mice (α2α1/α2α1, hγβA/hγβA, Humanised Non-Thalassemia Controls) 
were obtained from Dr Thomas Ryan, the University of Alabama at Birmingham U.S.A.15,19. Experimental proto-
cols were performed following the U.K Home Office Regulations and Guidelines for the Operations of Animals 
(Scientific Procedures) Act (1986) and approved by the local UCL animal welfare ethics committee. Mice were 
housed in single cages after plugging. The dams were given wet food after the laparotomy and closely monitored 
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for the first seven days after the procedure. The animal experiments were done according to the project license 
PPL No: 70/7408 and Animals [Scientific Procedures] Act 1986 and the NC3Rs ARRIVE guidelines 2013. The 
operator was personal licensee PIL 70/23796.
Lentiviral vector production. GLOBE Lentiviral vectors were produced as described using standard 
methods13,98. Compared to other transcription designs, GLOBE vector has only HS2 and HS3 which have the 
crucial LCR enhancer and chromatin-opening functions99,100. GLOBE-LV is a minimal LCR-β-globin transcrip-
tion unit containing a 2.7 kb fragment encompassing LCR elements HS2 and HS3, linked to a fully functional 
mini-β-globin gene with 265 bp of 5′ and 300 bp of 3′ flanking sequences; intron 2 features an internal deletion, 
reducing its size to 257 bp.
Uninjected control litters. Genotyping of control litters (n = 3) was performed at E18 to determine the 
proportion of heterozygous and homozygous pups.
In utero injections. IUGT was performed in timed-mated pregnant heterozygous thalassemia mice as 
described38,101 with minor modifications. On E13.5 day of gestation, the animals were shaved in the abdominal 
area; the skin was cleaned using ChloraPrep® and under 5% isoflurane (VetTech Solutions Ltd, UK) general 
anaesthesia, a midline laparotomy was performed, and the uterine horns exposed under sterile conditions. 20 μl 
(107 VP/ml) of Globe LV viral particles were injected through the myometrium into the hepatic region of each 
fetus using a 33-gauge needle (Hamilton, Switzerland). The uterus was returned to the maternal peritoneal cavity, 
the abdomen was closed using an absorbable vicryl 6-0 suture (Ethicon Inc., USA) and analgesia (Marcain, 0.25% 
AstraZeneca) was administrated. Mice were recovered in a warm cage (28 °C) overnight. After spontaneous deliv-
ery at E20-E21 day of gestation, treated pups were cross-fostered to CD1 dams by day 2–3 after birth, to avoid 
maternal cannibalism and maternal antibody response to the transgenic protein102–104. Pups were genotyped at 
three weeks of age; earlier genotyping was precluded by the Home Office Project license. The pups were bred until 
scheduled post-mortem examination at 12 and 32 weeks postnatal.
Post-mortem tissue harvest. At post-mortem examination, blood (0.5–1 ml) was collected by cardiac 
puncture under terminal anaesthesia, induced by injecting 0.8 ml of 1.25% Tribromoethanol (Avertin Sigma- 
Aldrich, UK) solution. The spleen and liver were placed in 1.5 ml Safe-Lock microtubes (Eppendorf, UK). For 
bone marrow collection, the femur and tibia were separated from the body and muscle was removed off the 
bones. The epiphysis was removed from both ends and placed in 1.5 ml Safe-Lock microtubes (Eppendorf, UK). 
All the tissues were snap frozen in liquid nitrogen and stored at −80 °C.
Isolation of bone marrow. The bone marrow was harvested by inserting a syringe needle (Terumo, myjec-
tor 27G, 0.4 x 12 mm, Belgium) into one end of the bone and flushing 1 ml of Phosphate Buffer Saline (1x PBS, 
pH 7.2) (Sigma, Life Sciences, USA) repeatedly through the bone. The bone marrow aspirates were collected into 
1.5 ml Eppendorf tubes and centrifuged at 300xg for 5 minutes to pellet the cells.
DNA Isolation and quantitation. DNA was isolated from bone marrow aspirates using Invitrogen 
PureLink Genomic DNA Mini kit (Cat No: K1820-01) as per manufacturer’s instructions. The concentration 
of the DNA samples was by the NanoDrop 1000 Spectrophotometer (Thermo Scientific, UK). The quality of the 
DNA samples was determined by calculating the A260/A280 ratio.
PCR for genotyping. Animals were genotyped using primers specific for mouse or human haemoglobin 
(Table 1). The reactions were done in 0.2ml polypropylene PCR tubes (Corning) in a Thermo Scientific thermal 
cycler using MyRedTaq PCR mix (Bioline).
Agarose gel electrophoresis. DNA samples were resolved by agarose gel (2%) electrophoresis in 1X 
Tris-Borate-EDTA (TBE) buffer. The agarose gel (2%) was made using 1XTBE plus SYBR DNA stain (1 in 10,000 
dilutions, Sigma-Aldrich). 1ul of DNA was loaded onto the gel and fragments resolved at 140V, 90mA for 45min-
utes. Nucleic acid fragments were visualised on a UV transilluminator (UVP®, USA) and photographed under 
ultraviolet light employing the Bio-Doc-ItTM System (UVP®).
RNA isolation and quantitation. RNA was extracted from blood and bone marrow samples of mice using 
the Bioline Isolate II RNA Mini kit (BIO-52072) manufacturer’s instructions. RNA from the human samples was 
extracted using TRIzol reagent (Invitrogen) per manufacturer’s instructions. RNA samples were quantitated using 
the Nanodrop 1000 spectrophotometer (Thermo Scientific, UK) and purity was ascertained by A260/280 ratio 
(>1.9).
qpcR using taqman® probes. Reverse Transcription: cDNA was synthesised by using Bioline Sensifast 
cDNA synthesis kit (Bio-65053). Taqman® oligonucleotide probes have been used in the qPCR experiments 
(Table 1) Real-time qPCR was done using the Bioline SensiFAST Probe Hi-ROX Kit (BIO-82002). The target 
genes included human β, γ globin. The qPCR reactions were performed in triplicates in 96- well optical plates 
(Microamp®, Applied Biosystems, N8010560).
The reactions were run on the Applied Biosystems Step-One Plus Real-Time PCR system machine. Results 
were analysed using the Life Technologies Step-One software.
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Determination of RNA expression levels by qPCR. Expression levels of human β and γ-globin chains 
(target genes) were assessed in the blood and bone marrow samples of treated and untreated mice at 12 weeks. 
The relative quantity of each target gene studied was calculated by the ΔΔCt method.
Assessment of vector copy number by qPCR. Viral titers were quantified by determination of inte-
grated viral copy number (VCN) in cell genomic DNA or unintegrated proviral vector genomes in the cytoplasm 
by a TaqMan® real-time qPCR method. The qPCR reactions were set-up in 96-well reaction plates (MicrAmpTM 
Optical; Applied Biosystems, USA) and analysed using Butler’s late reverse transcriptase (LRT) primer/probe 
set105.
The endogenous titin was used to determine absolute numbers of genomes present in each qPCR reaction 
using a primer/probe set. Titin, also called connectin, is a protein kinase involved in the structural assembly of 
microfilaments in muscle and during chromosome segregation and cell division in non-muscle cells. Standard 
curves were generated using serial dilutions (106 copies to 101 copies) of the GLOBE and the Titin plasmids 
(PGK plasmid)106 to determine copy number per cell[VCN per Cell = Number of Copies of GLOBEx2/Number 
of Copies of Titin].
Primers and probes. The primers already described in the literature19 were used for the study. The oligonu-
cleotides were custom-made from Eurofins MWG Operon, Germany (Table 1).
Haematological indices. Peripheral blood was collected from anaesthetised mice using a heparinised 
syringe into BD micro trainer EDTA collection tubes (Fisher Scientific). Red blood cell counts and Hematocrit 
values were measured. Hb concentrations were determined by Hemocue Hb 201+ system. Full blood counts and 
Serum Protein Electrophoresis (SPE) analysis for all the samples were performed by Central Diagnostics facility 
at the University of Cambridge. Animal and Spleen weight was also measured using a high precision balance 
(Kern, UK).
High-performance liquid chromatography analysis (HPLC). Red cells (20 μl) were lysed in 500 μl 
0.1M 2-mercaptoethanol/0.1M HCl and diluted to 1ml with 500 μl 50% aqueous acetonitrile. After centrifuga-
tion (13,000 rpm × 5 minutes), samples were transferred to HPLC autosampler vials and analyzed on a Grace 
Vydac 214TP C4 column (250 × 4.6 mm), using a gradient of solution A (water/acetonitrile/trifluoroacetic acid/
heptafluorobutyric acid, 700:300:0.7:0.1) and solution B (water/acetonitrile/trifluoroacetic acid/heptafluorobu-
tyric acid, 450:550:0.5:0.1). Proteins were detected using a Jasco MD-1510 detector and the area of globin chains 
quantified at 220 nm.
Gene Primers/probe
Melting (˚C) 
Temperature
LRT Forward TGT GTG CCC GTC TGT TGT GT 59.4
LRT Reverse GAG TCC TGC GTC GAG AGA GC 63.5
LRT Probe FAM -CAG TGG CGC CCG AAC AGG GA- TAM 65.5
mTitin forward AAA ACG AGC AGT GAC GTG AGC 59.8
mTitin reverse TTC AGT CAT GCT GCT AGC GC 59.4
mouse beta forward GCT GCT GGT TGT CTA CCC TTG 61.8
human gamma 
forward GTG GAA GAT GCT GGA GGA GAA 60.3
human beta forward CGT GCT GGT CTG TGT GCT G 61
mouse alpha forward AGC TGA AGC CCT GGA AAG GAT 59.8
human alpha forward CAG ACT CAG AGA GAA CCC ACC AT 62.4
mouse beta reverse CCC ATG ATA GCA GAG GCA GAG 61.8
Human gamma 
reverse TGC CAA AGC TGT CAA AGA ACC T 58.4
human beta reverse CTT GTG GGC CAG GGC ATT AG 61.4
mouse alpha reverse GCC GTG GCT TAC ATC AAA GTG 59.8
human alpha reverse GCC TCC GCA CCA TAC TCG 60.5
mouse beta probe FAM -CCA GCG GTA CTT TGA TAG CTT TGG AGA CC –TAM 68.1
human gamma probe FAM - AGG CTC CTG GTT GTC TAC CCA TGG ACC -TAM 69.5
human beta probe FAM - CCC ATC ACT TTG GCA AAG AAT TCA CCC -TAM 65
mouse alpha probe FAM -TGC TAG CTT CCC CAC CAC CAA GAC C -TAM 67.9
human alpha probe FAM -TGC TGT CTC CTG CCG ACA AGA CCA A -TAM 66.3
mTitin probe FAM - TGC ACG GAA GCG TCT CGT CTC AGT C -TAM 67.9
Mouse β KI reverse GTCAGAAGCAAATGTGAGGAGCA 62.5
β KI forward TTGAGCAATGTGGACAGAGAAGG 62.4
B383 KI reverse GTTTAGCCAGGGACCGTTTCA 62
Table 1. List of Primers used for genotyping and RT-qPCR.
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Imaging. Pearl Stains and H&E stains were visualised using a Zeiss AxioScan Z1 Slide Scanner. The images 
were processed using Zeiss-lite software 2012.
In vivo MRI. In vivo imaging, spleen volume, cardiac function and relaxometry were performed as described 
in L. Jackson et al.23, at 30 weeks of age using a 9.4T MR system (Agilent Technologies, Santa Clara, USA) 
equipped with 1000 mT/m gradient inserts and a 39mm volume resonator RF coil (RAPID Biomedical, Rimpar, 
Germany). A small animal physiological monitoring system (SA Instruments, Stony Brook, NY) was used to 
record the ECG trace, respiration rate, and internal temperature. Animals were anaesthetized with a mixture of 
isoflurane and oxygen with physiological measurements used to maintain the depth of anaesthesia23.
Cardiac function. Cardiac function was assessed with a gradient echo cine MRI sequence with a temporal 
resolution of 5.2 ms, an in-plane spatial resolution of 117 μm and a slice thickness of 1 mm23. The left ventricular 
blood pool was segmented at systole and diastole using Segment v1.8 R0462107 and the corresponding volumes 
used to calculate left ventricular ejection fraction (EF), stroke volume (SV) and end systolic/diastolic volumes 
(ESV/EDV)62.
Site integration studies. SI was performed by the Nationales Centrum für Tumorerkrankungen (NCT) 
Heidelberg, German Cancer Research Center (DKFZ), Department of Translational Oncology, Germany.
Statistical analysis. All the haematological indices in the different groups (IUGT 32 Weeks, IUGT 12 
Weeks, age-matched Humanised Non-Thalassemia Control, age-matched Uninjected Thalassemia Control 
group) were compared using one-way ANOVA with Bonferroni’s multiple comparison tests. For the qPCR data, 
statistical significance was determined by One Way ANOVA and Kruskal-Wallis test. To achieve a statistically 
meaningful result, for each group we aimed to have at least six mice pups in each group, born by more than three 
different dams, in order to have more than three independent biological replicates Graph Pad Prism Version 7.0a 
for MAC, Graph Pad Software, LA Jolla California, USA was used for statistical analyses and graph drawing.
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